Cell and gene therapies are upending the treatment of a growing number of diseases by addressing the underlying causes of genetic disorders. Yet the high costs associated with these therapies, sometimes costing multiple millions of dollars for a single treatment, pose significant challenges for patients, payers and healthcare systems. To address this matter, a growing…
Prominent cell and gene therapy vendors in 2023
In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030. The burgeoning demand in…
The top 100 cell and gene therapy companies to watch in 2023
The cell and gene therapy sector is poised to deliver a wave of new therapies with the potential to cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023. While manufacturing and regulatory challenges remain,…
FDA approves Bluebird Bio’s cell-based gene therapy Zynteglo
FDA announced that it had approved Zynteglo (betibeglogene autotemcel), a novel cell-based gene therapy for adult and pediatric patients with beta-thalassemia who need regular red blood cell transfusions. Zynteglo, developed by Bluebird Bio (Nasdaq: BLUE), is administered as a single dose. The product is indicated for adult and pediatric patients who need regular red blood…
50 leading cell and gene therapy companies
Cell and gene therapies promise to enable broad changes in the healthcare system over the next decade, prompting a growing number of cell and gene therapy companies to join the space. Consider that a cell therapy technique could eliminate the need for immunosuppressive drugs for some organ transplant patients. Cell and gene therapy companies also…